3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Carcinoma, Non-Small-Cell Lung
6
Carcinoma, Hepatocellular
6
Melanoma
5
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms
4
Small Cell Lung Carcinoma
3
Recurrence
3
Head and Neck Neoplasms
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Recurrent Squamous Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Mesothelioma
2
Lung Neoplasms
2
Liver Neoplasms
2
Fallopian Tube Neoplasms
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Vascular Neoplasms
1
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Testicular Neoplasms
1
Solid Tumor
1
Sarcoma, Synovial
1
Interventions
Carboplatin
23
Cisplatin
19
pembrolizumab
14
Paclitaxel
12
Gemcitabine
12
Pemetrexed
11
130-nm albumin-bound paclitaxel
9
Everolimus
8
Cetuximab
8
Fluorouracil
7
Axitinib
6
osimertinib
5
durvalumab
5
Sunitinib
5
Radiotherapy
5
Erlotinib Hydrochloride
5
Docetaxel
5
Cyclophosphamide
5
Albumin-Bound Paclitaxel
5
Sorafenib
4
Radiation
4
Nivolumab
4
Ipilimumab
4
vosaroxin
3
Radiotherapy, Intensity-Modulated
3
Octreotide
3
Irinotecan
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
pralsetinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma
×
tremelimumab
×
Clear all
NCT03703297
2025-11-21
ADRIATIC
AstraZeneca
Phase 3
Active not recruiting
730 enrolled
19 charts
1 FDA